ArticleJournal of the American College of Emergency Physicians open2025
National Emergency Department Registry for Mpox: Coordinating Multisite Surveillance Networks to Inform Current and Future Outbreaks.
Article in Journal of the American College of Emergency Physicians open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Despite many emergency departments (EDs) managing patients with possible mpox, individual institution reports have been limited, making it challenging to understand demographic trends and service needs. We established a data repository of ED patients with mpox to inform epidemiologic trends and future practice. Methods: This national multicenter retrospective chart review included patients aged ≥ 18 years presenting to 8 EDs across the United States during the mpox outbreak (June 2022 to January 2023) with laboratory-confirmed mpox. Data were collected on demographic variables and clinical characteristics from each participating site, representing the northeast, midwest, south, and west regions. Results: A total of 270 patients were included in the cohort; most were men (264, 98%) and relatively young (median age: 34 years; IQR: 28-41). Patients commonly presented with skin lesions (253, 94%), fever or flu-like symptoms (152, 56%), and rectal pain (70, 26%). More than half (141/270, 52%) of individuals had a known diagnosis of HIV. Among those tested for sexually transmitted infection (STI) coinfection, 36% (51/143) had positive syphilis serology (not all diagnoses could be confirmed by clinical history), followed by gonorrhea 7% (9/128) and chlamydia 7% (8/122). Conclusion: Similar to the COVID-19 pandemic, EDs played a critical role in the mpox response. High coinfection rates with STIs highlight the need for routine coinfection testing. Multisite data collection identified key trends, emphasizing the value of surveillance networks for outbreak response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.